
With patients buying gray-market peptides, HHS’s draft policy aims to reunite prescribers, patients, and pharmacists around these emerging products.
According to a recent statement released by the American Academy of Pediatrics (AAP), the low reimbursement rates from insurance companies to providers for the cost of providing vaccines to children is a risk to their health.






